TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note published on Wednesday morning. The brokerage issued a hold rating on the stock.

TherapeuticsMD Stock Up 0.7 %

Shares of NASDAQ TXMD opened at $1.42 on Wednesday. TherapeuticsMD has a 1-year low of $1.15 and a 1-year high of $2.84. The stock has a fifty day moving average price of $1.53 and a 200 day moving average price of $1.74.

Institutional Inflows and Outflows

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP lifted its position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the quarter. Clearline Capital LP owned about 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent filing with the SEC. 30.74% of the stock is currently owned by institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.